Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 53: 807-809, 2007; 10.1373/clinchem.2007.085480
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ueland, P. M.
Right arrow Articles by Clarke, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ueland, P. M.
Right arrow Articles by Clarke, R.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Nutrition
Right arrow Hemostasis and Thrombosis
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 2007;53:807-809.)
© 2007 American Association for Clinical Chemistry, Inc.

Editorials

Homocysteine and Cardiovascular Risk: Considering the Evidence in the Context of Study Design, Folate Fortification, and Statistical Power

Per Magne Ueland1,a and Robert Clarke2,3

1 Section for Pharmacology, Institute of Medicine, University of Bergen, and, Haukeland University Hospital, Bergen, Norway
2 Clinical Trial Service Unit and, 3 Epidemiological Studies Unit, University of Oxford, Oxford, United Kingdom

aAddress correspondence to this author at: Section for Pharmacology, Institute of Medicine, University of Bergen, 5021 Armauer Hanssen Hus, Bergen, Norway. Fax 47-55-974605; e-mail per.ueland@ikb.uib.no.

The first 300 words of the full text of this article appear below.

The hypothesis that moderately increased plasma total homocysteine (tHcy) concentrations are causally related to cardiovascular disease (CVD) originated from observations of vascular disease in patients with homocystinuria (1). tHcy concentrations are ~10-fold higher in patients with untreated homocystinuria than in the general population, and these patients often suffer from CVD in early life. Homocystinuria may arise from one of several rare defects in genes involved in methionine metabolism, resulting in high tHcy concentrations, with cystathionine ß-synthase (CBS gene) deficiency being the most common. In responsive cases of homocystinuria, dietary supplementation with B-vitamins and betaine is remarkably effective at lowering plasma tHcy concentrations and decreasing the risk of CVD (2). In addition to suggesting that extremely high tHcy concentrations may be causally related to CVD in affected individuals with homocystinuria, McCully also suggested that moderately increased tHcy concentrations may be related to CVD risk in the general population (1).

A single discrete mechanism of vascular injury has not been identified, but high homocysteine may have adverse effects on platelet function and clotting factors and may increase vascular smooth muscle cell proliferation. Furthermore, increased homocysteine concentrations provoke endothelial dysfunction, possibly mediated by oxidative stress or interference with nitric oxide function (3)(4).

Over the last 3 decades, many observational epidemiological studies have reported associations between increased tHcy concentrations and risk of coronary heart disease (CHD) and stroke (5). Although results of prospective cohort studies (in which blood for tHcy determination was collected before the onset of disease) have been weaker and more inconsistent than those of retrospective studies (in which the blood was collected after the onset of disease), prospective studies are more reliable because they are not vulnerable to bias due to the effect of disease on tHcy ("reverse . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
R. M. van Dam
Coffee Consumption and Coronary Heart Disease: Paradoxical Effects on Biological Risk Factors versus Disease Incidence
Clin. Chem., September 1, 2008; 54(9): 1418 - 1420.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
P. M. Ueland
Importance of Chemical Reduction in Plasma and Serum Homocysteine Analysis
Clin. Chem., June 1, 2008; 54(6): 1085 - 1086.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
P. M. Ueland and S. Hustad
Homocysteine and Folate Status in an Era of Folic Acid Fortification: Balancing Benefits, Risks, and B-vitamins
Clin. Chem., May 1, 2008; 54(5): 779 - 781.
[Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
L. B Bailey
The rise and fall of blood folate in the United States emphasizes the need to identify all sources of folic acid
Am. J. Clinical Nutrition, September 1, 2007; 86(3): 528 - 530.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Association for Clinical Chemistry.